Following Alzheimer’s drug approval, analysts dish on what they expect from Biogen in 2023
Biogen has been on a roller coaster over the past couple of years. It survived the controversial approval and disastrous rollout of its first Alzheimer’s drug Aduhelm after data on its second drug showed promise. And it got accelerated approval earlier this month for that drug, to be marketed as Leqembi.
New CEO Chris Viehbacher is spearheading a new strategy, hoping to turn Leqembi into a full approval later this year and march Biogen on the comeback path. But industry analysts have their own ideas about what to expect following the annual JP Morgan Healthcare Conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.